Fundraising Fox
ABLi Therapeutics
Atlanta, US · Founded 2025 · Delaware corporation
Find your way into ABLi Therapeutics
Sign up to see every warm intro you have to ABLi Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ABLi Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ABLi Therapeutics develops small molecule inhibitors targeting Abelson tyrosine kinases (c-Abl) to treat Parkinson's disease, Parkinson's-related neurodegenerative diseases, and other neurological conditions linked to Abl kinase dysfunction. Its RAMP drug innovation engine designs Abl kinase inhibitors, including its lead candidate risvodetinib, aimed at improved brain penetration, potency, and safety.
Founders & leadership
ABLi Therapeutics was founded in 2025 by Milton H. Werner.
MH
Milton H. WernerChief Executive Officer, President, and SecretaryMilton H. Werner previously founded and served as President and CEO of Inhibikase Therapeutics, where he developed protein kinase inhibitors targeting neurodegenerative diseases including Parkinson's disease. He holds a research background from Rockefeller University and has led private and public biotech companies through capital raises and market valuations.
Board
JY
Jeffrey YoungBoard director
AD
Anastasia DaifotisBoard director
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 round · 2025
▶$1MraisedJan 2026 · 10 investors · PharmaceuticalsRule 506(b)
▶$1MraisedJan 2026 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey YoungDirector
- Milton H. WernerExecutive Officer, Director
- Garth Lees-RolfeExecutive Officer
- Anastasia DaifotisDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
AbilityAbility is a biotechnology company developing highly-selective, immune cell-modulating antibody therapeutics for patients with inflammatory diseases and cancer. Its AbiLeap discovery engine uses AI and a database of antibody sequences to generate fully-human monospecific and bispecific antibodies, with a lead program targeting inflammatory skin diseases and other candidates for solid tumors.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ADvantage TherapeuticsADvantage Therapeutics is a biopharmaceutical company engaged in therapeutic drug development and clinical research, including NIH/PHS-funded studies evaluating the safety and effectiveness of drugs and treatments.
Abilita TherapeuticsAbilita Therapeutics is a drug discovery company focused on membrane protein targets, using its EMP (Enabled Membrane Proteins) technology based on directed evolution to create stability- and expression-enhanced protein variants for discovering and optimizing drug candidates.
AblivaAbliva develops treatments for primary mitochondrial disease, a rare orphan disease caused by impaired cellular energy metabolism in the mitochondria. The company focuses on pharmaceutical research and development to address an unmet medical need where no effective treatments currently exist.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Companies working in the same space as ABLi Therapeutics.
Frequently asked questions
- What does ABLi Therapeutics do?
- ABLi Therapeutics develops small molecule inhibitors targeting Abelson tyrosine kinases (c-Abl) to treat Parkinson's disease, Parkinson's-related neurodegenerative diseases, and other neurological conditions linked to Abl kinase dysfunction. Its RAMP drug innovation engine designs Abl kinase inhibitors, including its lead candidate risvodetinib, aimed at improved brain penetration, potency, and safety.
- Who founded ABLi Therapeutics?
- ABLi Therapeutics was founded by Milton H. Werner in 2025.
- How much funding has ABLi Therapeutics raised?
- ABLi Therapeutics has disclosed $1M raised across 1 round.
- Where is ABLi Therapeutics headquartered?
- ABLi Therapeutics is headquartered in Atlanta, US.